Dermatomyositis

Related records

Broader conditions (21)

• Acquired idiopathic inflammatory myopathy
• Acquired skeletal muscle disease
• Connective tissue disorder
• Dermatitis
• Disease
• Disease by body system or component
• Disease by developmental or physiological process
• Disease by etiologic mechanism
• Human disease
• Idiopathic disease
• Idiopathic inflammatory myopathy
• Inflammatory disease
• Integumentary system disorder
• Muscle tissue disorder
• Musculoskeletal system disorder
• Myopathy
• Myositis disease
• Polymyositis
• Rheumatic disorder
• Skeletal muscle disorder

Narrower conditions (13)

• Adermatopathic dermatomyositis
• Adult dermatomyositis
• Amyopathic dermatomyositis
• Anti-MDA5 dermatomyositis
• Anti-Mi2 dermatomyositis
• Anti-NXP2 dermatomyositis
• Anti-SAE dermatomyositis
• Anti-TIF1 dermatomyositis
• Classical dermatomyositis
• Clinically amyopathic dermatomyositis
• Hypomyopathic dermatomyositis
• Juvenile dermatomyositis
• Neonatal dermatomyositis

Trials (181)

• 3T Therapy in the Treatment of MDA5-positive Dermatomyositis
• A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis
• A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy
• A Clinical Trial for CTD-ILD Treatment
• A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
• A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases
• A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis
• A Pilot Study of Etanercept in Dermatomyositis
• A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis
• A Study In Adults With Moderate To Severe Dermatomyositis
• A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
• A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
• A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
• A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments
• A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
• A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
• A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)
• A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis
• A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis

Approved drugs (3)

• Cortisone acetate
• Prednisolone
• Prednisone

Drugs in development (44)

• Abatacept Phase 3
• Aldesleukin Phase 3
• Anakinra Phase 2
• Anifrolumab Phase 3
• Apremilast Phase 2
• Baricitinib Phase 3
• Bazlitoran Phase 2
• Belimumab Phase 2
• Brepocitinib Phase 3
• Corticotropin Phase 2
• Cyclophosphamide Phase 2
• Cyclosporine Phase 2
• Daxdilimab Phase 2
• Dazukibart Phase 2
• Deucravacitinib Phase 2
• Eculizumab Phase 2
• Efgartigimod alfa Phase 2
• Empasiprubart Phase 2
• Enpatoran Phase 2
• Etanercept Phase 2

Other linked drugs (3)

• Atorvastatin
• Lenalidomide
• Lenalidomide hydrochloride monohydrate